ROS1 fusion clinical trials research targeted treatments for the ROS1 gene mutation in cancers, which is present in several cancer types, such as non-small cell lung cancer (NSCLC), lymphoma, colorectal cancer, stomach cancer, ovarian cancer, and more. The ROS1 gene is responsible for cell growth and signaling, so mutation can cause overproduction of cells.
ROS1 fusion clinical trials are important because those patients affected by these cancers with the ROS1 gene mutation can access targeted therapies that are specialized to their specific genetic mutation, rather than the standard treatment. For patients with genetic mutations, targeted therapies offer new hope for when standard treatment is not effective.
There are ROS1 fusion clinical trials available for enrollment now. Most of which are available for NSCLC, because it was the first type of cancer identified with this genetic mutation. Common drugs being studied in ROS1 fusion clinical trials for NSCLC include: Crizotinib (Xalkori), Entectinib, Lorlatinib, Ceritinib, Dacomitinib, Gefitinib, and Pembrolizumab.
How to Participate in ROS1 Fusion Clinical Trials?
ROS1 fusion clinical trials have eligibility requirements for enrollment. For patients looking for ROS1 fusion clinical trials, or clinical trials for any cancer type or genetic mutation, there are tools that can find clinical trials that are right for your specific cancer case. The SYNERGY-AI Clinical Trial Matching System from Massive Bio pre-screens patients for trials in the United States, taking into consideration geographical location, cancer type, biomarker status, and more.